



## **Prurigo nodularis Liga (PNL)**

**Location:**

**Center for Chronic Pruritus (KCP). Executive committee:** Prof. Dr. S. Ständer, Prof. Dr. M. Augustin, Dr. H. Ständer  
Von-Esmarch-Straße 58, 48149 Münster. E-mail: [pnl@ukmuenster.de](mailto:pnl@ukmuenster.de); T +49 (0)2 51 - 83 - 56510; F +49 (0)2 51 - 83 - 57322

Münster, September 19th, 2018

Dear supporters of the Prurigo Nodularis League,

Please find the 5th newsletter for our initiative attached. We are pleased to share we recently celebrated the 10<sup>th</sup> anniversary of the Center for Chronic Pruritus (KCP) as well as announce the initiation of a German Research Association research project that will closely examine chronic prurigo. In addition, multiple clinical studies will begin this autumn that will test the antipruritic efficacy of different substances on chronic prurigo.

Enjoy the newsletter!

Your executive committee

Become a supporter! E-mail: [EmilyRose.Burnett@ukmuenster.de](mailto:EmilyRose.Burnett@ukmuenster.de)

## **DFG**



The German Research Foundation (DFG) is providing funding for the FOR2690 projects, a research initiative of German experts working to explore the mechanisms behind pruritus. The results of their work could lead to more effective therapies in the future.

## **Pruritus Symposium**



The 6th Münster Pruritus Symposium recently took place in Münster, Germany. A biannual, interdisciplinary event, it seeks to educate physicians and researchers on pruritus, an area of medicine that has yet to be added to the official medical curriculum. This year's Symposium was a great success with over 280 participants

who came to learn about the role of inflammation in pruritus and pruritus in the elderly, among other things.

### **KCP Celebrates 10 Years**



The interdisciplinary Center for Chronic Pruritus (KCP) turned 10 this year! It was founded in 2008 as the first outpatient center for pruritus and treats not only German patients, but many patients with chronic pruritus from abroad. The goal of the KCP members is to provide relief to patients suffering with pruritus despite the lack of approved treatments worldwide.

### **Linear Prurigo**

After chronic prurigo was defined as an own disease and umbrella term for the various clinical subtypes of chronic prurigo in February 2017, a new subtype, linear prurigo, was outlined at a consensus conference in Brussels in April 2018. This variant, characterized by the presence of itchy, linear and scarring scratch lesions, shares common clinical properties with other subtypes of chronic prurigo and should be differentiated from skin picking syndromes.



## Continuing Medical Education (CME)



At Euroderm Excellence, a continuing medical education (CME) seminar held in Nice for young assistant physicians from across Europe, participants were taught about chronic prurigo in order to raise awareness.



## **Sciderm**

In May 2018, scientists and dermatologists met for a continuing medical education (CME) seminar in Münster, Germany. The potential to connect basic sciences and clinics, in particular, was met with great interest and demonstrated just how essential and promising a cooperation can be. This is especially true for research on pruritus and prurigo, as new pathomechanisms and therapies can be developed based on basic research.

## **Congresses**

In the past year, many presentations on chronic prurigo have taken place at congresses, for example:

- **The annual meeting of the American Academy of Dermatology in San Diego, California, USA**



- **The Pruritus Research Working Group meeting at the ADF in Zurich, Switzerland**



- **The EADV Spring Symposium in Budva, Montenegro**



## **New Therapeutic Approaches for Chronic Prurigo**

Our Center for Innovative Dermatology (ZiD) offers two new therapeutic agents for patients with chronic prurigo:

- 1) In a phase III study, a neurokinin-1 receptor antagonist will be compared to placebo during the first 10 weeks, followed by an open label treatment.
- 2) Promising results are also expected from a study with a partial opioid receptor antagonist compared to placebo for 16 weeks and then given to all participants in an open label extension period.

For further information, please contact our study center per e-mail ([zid@ukmuenster.de](mailto:zid@ukmuenster.de)) or telephone (0049-251-8356558).